Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ArriVent BioPharma (AVBP) EBITDA (2023 - 2026)

ArriVent BioPharma has reported EBITDA over the past 4 years, most recently at -$43.6 million for Q1 2026.

  • Quarterly results put EBITDA at -$43.6 million for Q1 2026, up 32.07% from a year ago — trailing twelve months through Mar 2026 was -$145.5 million (down 14.14% YoY), and the annual figure for FY2025 was -$166.1 million, down 105.81%.
  • EBITDA reached -$43.6 million in Q1 2026 per AVBP's latest filing, down from -$35.7 million in the prior quarter.
  • Across five years, EBITDA topped out at -$12.2 million in Q1 2023 and bottomed at -$64.2 million in Q1 2025.
  • Median EBITDA over the past 4 years was -$22.6 million (2023), compared with a mean of -$28.1 million.
  • The largest annual shift saw EBITDA crashed 268.57% in 2025 before it skyrocketed 32.07% in 2026.
  • Over 4 years, EBITDA stood at -$23.1 million in 2023, then rose by 9.84% to -$20.8 million in 2024, then tumbled by 71.45% to -$35.7 million in 2025, then fell by 22.01% to -$43.6 million in 2026.
  • Business Quant data shows EBITDA for AVBP at -$43.6 million in Q1 2026, -$35.7 million in Q4 2025, and -$34.8 million in Q3 2025.